PF-06940434 / Pfizer - LARVOL DELTA

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=85 | Terminated | Sponsor: Pfizer | Active, not recruiting ➔ Terminated; Study termination was based on strategic considerations and not due to specific safety reasons or a request from a regulatory authority.

Trial termination • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • PD-L1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=85 | Active, not recruiting | Sponsor: Pfizer | Trial completion date: Aug 2024 ➔ Dec 2024 | Trial primary completion date: Aug 2024 ➔ Dec 2024

Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • PD-L1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=75 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=195 ➔ 75 | Trial completion date: Oct 2025 ➔ Jul 2024 | Trial primary completion date: Oct 2025 ➔ Jul 2024

Enrollment change • Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • PD-1 • PD-L1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=195 | Recruiting | Sponsor: Pfizer | N=104 ➔ 195

Enrollment change • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • PD-1 • PD-L1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Pfizer | Trial completion date: Feb 2025 ➔ Oct 2025 | Trial primary completion date: Feb 2025 ➔ Oct 2025

Metastases • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • PD-1 • PD-L1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Pfizer | Trial completion date: Nov 2023 ➔ Feb 2025 | Trial primary completion date: Nov 2023 ➔ Feb 2025

Metastases • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • PD-1 • PD-L1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=104 | Recruiting | Sponsor: Pfizer | Active, not recruiting ➔ Recruiting | N=69 ➔ 104 | Trial completion date: Aug 2023 ➔ Nov 2023 | Trial primary completion date: Aug 2023 ➔ Nov 2023

Enrollment change • Enrollment open • Metastases • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • PD-1 • PD-L1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1 | N=69 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=122 ➔ 69

Enrollment change • Enrollment closed • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Melanoma • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • PD-1 • PD-L1

Study of PF-06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1; N=104; Recruiting; Sponsor: Pfizer; Trial completion date: Jan 2024 ➔ Jun 2023; Trial primary completion date: Jan 2024 ➔ Jun 2023

Clinical • Trial completion date • Trial primary completion date • Biliary Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Head and Neck Cancer • Hepatology • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer • PD-1

Study of PF‑06940434 in Patients With Advanced or Metastatic Solid Tumors. (clinicaltrials.gov) - P1; N=104; Recruiting; Sponsor: Pfizer; Trial completion date: May 2023 ➔ Mar 2024; Trial primary completion date: May 2023 ➔ Mar 2024

Clinical • Trial completion date • Trial primary completion date • Biliary Cancer • Bladder Cancer • Cholangiocarcinoma • Endometrial Cancer • Esophageal Cancer • Gastric Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Melanoma • Oncology • Ovarian Cancer • Pancreatic Cancer • Renal Cell Carcinoma • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Urothelial Cancer